NEW YORK, April 4  -Two weeks after penning a SNP collaboration with AstraZeneca, Lynx Therapeutics has agreed to perform gene expression assays for the Anglo-Swedish pharmaceutical giant using its MegaSort gene expression detection technology, Lynx said Wednesday.

Under the agreement, AstraZeneca will provide Lynx with tissue samples to analyze for differential gene expression patterns, and will make undisclosed milestone payments to Lynx. The parties did not disclose further terms of the agreement.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.